Revelation Biosciences, Inc. — Three and Nine Months Ended September 30, 2026 Earnings Summary

Revelation Biosciences, Inc. reported a net loss of $3.3 million for the three months ended September 30, 2026, and $9.6 million for the nine-month period. The company's cash and cash equivalents decreased to $9.1 million as of September 30, 2026, from $10.7 million at the end of 2025, though management believes current funds are sufficient to operate through the second quarter of 2027. Corporate highlights include the selection of a global contract research organization for an upcoming study on its lead candidate, Gemini, for acute kidney injury and the release of a market assessment projecting a $94 billion total addressable market for the drug. Gemini is a proprietary TLR4 agonist currently being evaluated for multiple indications including acute and chronic kidney disease, severe burns, and post-surgical infection prevention.